Patent intelligence · US
US 12404337
Compositions, doses, and methods for treatment of thyroid eye disease
Compositions, doses, and methods for treatment of thyroid eye disease
Patent details — US 12404337
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 2, 2025
- Expiration
- Aug 28, 2045
- Applicant
- Viridian Therapeutics, Inc.
- Claims
- 8
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545
Quick answer
US 12404337 (Compositions, doses, and methods for treatment of thyroid eye disease) is held by Viridian Therapeutics, Inc.. Status: granted. Granted Sep 2, 2025. Expires Aug 28, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Viridian Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K2039/55, A61P
More from Viridian Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12404337?
US 12404337 (Compositions, doses, and methods for treatment of thyroid eye disease) is held by Viridian Therapeutics, Inc.. Status: granted. Granted Sep 2, 2025. Expires Aug 28, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12404337?
Viridian Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 12404337 expire?
Our index shows an expiration date of Aug 28, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.